WASHINGTON, July 23 -- National Institutes of Health has issued a notice called: Prospective Grant of an Exclusive Patent License: RXFP1 AGONISTS.
The notice was published in the Federal Register on July 23 by Joni L. Rutter, Director, Office of the Director, National Center for Advancing Translational Sciences, National Institutes of Health.
Summary: The National Center for Advancing Translational Sciences, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the SUPPLEMENTARY INFORMATIONsection of this Notice to Modala Bio, Inc. (Modala), headquartered in De...